Reaction

Disseminated Aspergillosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 463 reports · 45 co-occurring drugs

As of the last recalculation, Disseminated Aspergillosis appears in 463 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is MICAFUNGIN SODIUM (PRR 641.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Micafungin Sodium	96	641.9	649.3
Cefazolin	63	359.2	361.7
Cefazolin Sodium	78	349.7	352.0
Voriconazole Injection	85	215.3	216.2
Amphotericin B	49	196.5	197.3
Pegaspargase	40	160.7	161.2
Voriconazole	87	158.3	158.8
Filgrastim	100	152.2	152.6
Mesna Injection	25	143.7	144.2
Mesna	25	141.1	141.5
Basiliximab	31	126.9	127.3
Cytarabine	106	102.6	102.7
Valganciclovir Hydrochloride Powder,	24	93.2	93.4
Mercaptopurine	32	89.0	89.2
Etoposide	107	84.8	84.9
Remdesivir	18	63.1	63.2
Valganciclovir	25	63.0	63.0
Valganciclovir Hydrochloride	25	63.0	63.0
Daptomycin	12	60.0	60.1
Itraconazole	15	59.6	59.7
Leucovorin Calcium	24	59.5	59.6
Metoclopramide Hydrochloride	79	55.3	55.3
Vincristine Sulfate	32	52.7	52.7
Ceftriaxone	34	50.2	50.2
Tacrolimus Ointment 0.1%	101	46.4	46.4
Tacrolimus Extended-Release Capsules	101	46.2	46.3
Cyclosporine	90	44.9	44.9
Meropenem	30	44.9	44.9
Ceftriaxone Sodium	35	44.3	44.3
Ursosiol	18	43.3	43.3
Dexamethasone 1.5 Mg	175	42.6	42.6
Cyclophosphamide Injection, Solution	123	42.2	42.2
Cyclophosphamide	123	42.2	42.2
Cyclophosphamide For Injection	123	42.2	42.2
Dexamethasone	175	42.0	42.0
Ondansetron Hydrochloride	88	39.6	39.6
Ursodiol	18	38.6	38.6
Tacrolimus	103	37.7	37.8
Terbinafine Hydrochloride	7	36.0	36.0
Ganciclovir Sodium	8	34.6	34.6
Ganciclovir	7	31.2	31.2
Piperacillin Sodium,Tazobactam Sodium	17	29.9	29.9
Piperacillin And Tazobactam	8	28.6	28.6
Baricitinib	6	28.3	28.3
Cefepime	8	25.5	25.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.